Mechanism
GLP-1R agonist; GIPR antagonist
Assets acting on this target.
- Class
- Bispecific GLP-1 receptor agonist/GIP receptor antagonist
- Notes
- Source: Veniant MM et al., Nature Metabolism 2024 (PMID 38316982, https://pmc.ncbi.nlm.nih.gov/articles/PMC10896721/): "AMG 133 (maridebart cafraglutide) is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers." Split from 'GLP-1/GIP receptor (dual)' (dual agonists) on 2026-09-28.